Theravance Biopharma, Inc.
TBPHNASDAQ
Healthcare
Biotechnology
$16.03
+0.19(1.2%)
52W $8.32 – $20.74
Quick:
8-K
Mar 30, 2026 (1 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
10-K
Mar 23, 2026 (2 weeks ago)Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures
8-K
Mar 19, 2026 (2 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Mar 3, 2026 (1 months ago)Current Report
Material event disclosure
Event materiality and market reaction
SCHEDULE 13G/A
Feb 17, 2026 (1 months ago)Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
8-K
Jan 12, 2026 (2 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Dec 8, 2025 (3 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Nov 12, 2025 (4 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Nov 10, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Aug 25, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Aug 20, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Aug 13, 2025 (7 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Aug 12, 2025 (7 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jun 26, 2025 (9 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jun 6, 2025 (10 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jun 2, 2025 (10 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
May 12, 2025 (10 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
May 8, 2025 (11 months ago)Current Report
Material event disclosure
Event materiality and market reaction
SCHEDULE 13G/A
Apr 30, 2025 (11 months ago)Beneficial Ownership (Amendment)
Large shareholder position disclosure
Ownership threshold, passive vs active
10-K
Mar 7, 2025 (1 years ago)Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures